The Mounjaro Shortage in the UK: Facts, Causes and Your Options

The biggest myth: 'Mounjaro has completely run out in the UK'

This one circulates every time a headline picks up on a supply blip. The reality is more granular. There has never been a point at which every strength of Mounjaro disappeared simultaneously from the entire UK market. What has happened (repeatedly since late 2023) is that demand for specific doses, particularly the 7.5mg, 10mg and 12.5mg strengths used by patients already on treatment, has outpaced the volume Eli Lilly could deliver in a given month.

That distinction matters. A patient who has never started Mounjaro and needs 2.5mg is in a different position from someone stabilised on 12.5mg whose pharmacy can't fulfil their monthly repeat. Conflating the two creates unnecessary panic, and a bit of that panic has fed the shortage itself: patients hearing rumours of a full-market drought have sometimes requested extra supplies 'just in case', which worsens the real shortfall for everyone else.

If you're researching Mounjaro shortages in the UK because you're considering starting treatment, the situation is not as stark as some coverage suggests. Current availability should always be confirmed with a registered pharmacy at the point of consultation.

Why the shortage of Mounjaro developed in the first place

Tirzepatide's UK weight-management licence arrived in November 2023. NICE recommended it for NHS use in December 2024, an endorsement that expanded awareness and demand dramatically, even among patients seeking private treatment. Manufacturing GLP-1 receptor agonist medicines is technically complex: the active molecule requires specialist synthesis and fill-finish capacity that cannot be scaled up overnight.

Eli Lilly invested heavily in expanding production, but the ramp-up lagged behind a demand curve that moved faster than most forecasts anticipated. The result was a tirzepatide shortage that rippled through both the NHS and private supply channels. You can read more detail on the broader supply picture on our tirzepatide shortage page, which tracks the manufacturing context.

A further pressure came from off-label use: before the weight-management licence, some patients had been prescribed tirzepatide for type 2 diabetes, and when demand from weight-management patients surged, both pools competed for the same stock. If you've been asking whether there is currently a shortage of Mounjaro and want a clear answer, regulatory guidance has since tightened prioritisation, and Lilly's UK supply agreements have improved the position substantially heading into 2025 and 2026.

How UK pharmacies and prescribers are managing the Mounjaro UK shortage

Regulated pharmacies are not simply passive in a supply crunch. A GPhC-registered pharmacy is expected to source medicines through the licensed UK supply chain, notify patients promptly if a dose is unavailable, and never substitute an unlicensed or unverified product. That last point is critical: the MHRA has warned publicly about counterfeit weight-loss pens sold online, some containing insulin rather than tirzepatide. Buying from unverified sellers to sidestep a shortage carries serious clinical risk, not just a legal one.

When a specific dose strength is temporarily constrained, a prescriber may discuss options: waiting for restocking, holding at a current dose rather than titrating, or in some cases adjusting the plan. What a prescriber should never do (and what patients should never do unilaterally) is skip doses without guidance or source medicine from outside the legitimate supply chain. The NHS provides clear advice on tirzepatide and what to do if you miss a dose, and your prescriber is the right first call if your supply is interrupted.

If you're weighing up the cost implications of private treatment during a period when prices have shifted with supply, our guide to Mounjaro value in the UK sets out what an honest private prescription actually includes.

What to do if your Mounjaro supply is interrupted right now

First, contact your prescribing pharmacy or prescriber before you run out, not on the last day of your current pen. Most supply gaps can be anticipated a week or two ahead, which gives more options. A prescriber can advise whether it's clinically reasonable to hold at your current dose for an extra week or two while stock is sourced, or whether a different plan is warranted.

Second, check the latest Mounjaro shortage update for current stock information, which is refreshed more frequently than published news. The picture around the Mounjaro weight-loss jab shortage has improved materially since the worst of the 2024 disruption, and many dose strengths are now consistently available through regulated private pharmacies.

Third, resist the pressure to buy from any source that doesn't require a prescription and clinical assessment. A question our prescribers hear regularly is whether it's safe to get medication from a social media seller or a site offering it without a consultation. It isn't. The safety infrastructure around legitimate supply (verified identity, clinical review, supply-chain provenance) exists for your protection, not as a commercial hurdle.

If you're ready to explore whether Mounjaro is clinically suitable for you, our team at nume reviews consultations the same day they're submitted, with next-working-day delivery once approved. Check your eligibility when you're ready.